XORTX Therapeutics (CSE:XRX) recently announced the appointment of Dave Matthews as CFO, replacing John Meekison, who acted as interim CFO for XORTX since the company’s founding. Mr. Meekison will remain with XORTX to assist with the transition.
Mr. Matthews brings more than 25 years of life sciences experience to XORTX.
As CFO and a key member of senior management for a number of companies, he was involved in raising more than $300-million in financing and negotiated and operated numerous joint ventures, strategic alliances and license agreements.
In a statement, Dr. Allen Davidoff, CEO of XORTX, said Mr. Matthews brings a strong track record of initiating, closing and managing fund raising efforts as well as an impressive number of licensing deals with big pharmaceutical companies.
Mr. Matthews added that XORTX is pursuing an interesting strategy focused on the acquisition of de-risked assets in orphan diseases. “I look forward to working with the XORTX team to support the development of these assets to provide useful therapeutic options to patients.”